Valuation : Cipher Pharmaceuticals Inc.

Market Cap 355M 255M 220M 206M 188M 24.39B 356M 2.45B 954M 12.31B 958M 937M 40.82B P/E 2026 *
12.4x
P/E 2027 * 11.2x
Enterprise Value 355M 255M 220M 206M 188M 24.39B 356M 2.45B 954M 12.31B 958M 937M 40.82B EV / Sales 2026 *
5x
EV / Sales 2027 * 4.29x
Free-Float
57.65%
Yield 2026 *
-
Yield 2027 * -
1 day-1.48%
1 week-1.06%
Current month-17.11%
1 month-15.25%
3 months-16.42%
6 months-7.55%
Current year-7.37%
1 week 13.95
Extreme 13.95
14.31
1 month 13.51
Extreme 13.51
18.46
Current year 13.51
Extreme 13.51
20.56
1 year 12.48
Extreme 12.48
20.56
3 years 3.96
Extreme 3.96
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap.
6/24/26 Option

Director

2,500 0.0098%
3/27/26 Option

Chief Executive Officer

83,902 0.3307%
3/27/26 Option

Chief Executive Officer

83,902 0.3307%
Change 5-day change 1-year change 3-year change Capi.($)
-1.48%-1.06%-12.43%+251.39% 255M
-0.13%-6.44%+60.34%+114.35% 1,047B
+0.85%-0.81%+51.29%+63.71% 646B
-1.03%-3.58%+21.43%+72.25% 451B
-1.46%-4.50%+37.80%+37.01% 355B
-0.72%-2.89%+22.32%+37.60% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-1.05%-1.57%+50.30%+67.68% 234B
+0.08%-1.78%-17.64%-54.11% 203B
-2.14%-0.30%+28.95%+87.59% 181B
Average -0.83%-2.51%+24.39%+68.90% 365.95B
Weighted average by Cap. -0.46%-3.46%+38.17%+65.91%

Financials

2026 *2027 *
Net sales 70.88M 51.01M 43.96M 41.22M 37.62M 4.88B 71.1M 489M 191M 2.46B 192M 187M 8.16B 82.69M 59.52M 51.29M 48.09M 43.9M 5.69B 82.96M 571M 223M 2.87B 223M 219M 9.52B
Net income 27.59M 19.86M 17.11M 16.04M 14.64M 1.9B 27.68M 190M 74.26M 958M 74.55M 72.93M 3.18B 32.49M 23.39M 20.15M 18.89M 17.25M 2.24B 32.59M 224M 87.46M 1.13B 87.8M 85.89M 3.74B
Net Debt - -
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-08-28 $13.95 -1.48% 55,238
26-08-27 $14.16 +0.43% 16,875
26-08-26 $14.10 -0.42% 24,400
26-08-25 $14.16 +0.43% 29,275
26-08-24 $14.10 0.00% 85,694
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.95CAD
Average target price
19.95CAD
Spread / Average Target
+43.01%

Quarterly revenue - Rate of surprise